Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Ipilimumab Monotherapy In Patients With Pretreated Advanced Melanoma: A Randomised, Double-blind, Multicentre, Phase 2, Dose-ranging Study.

J. Wolchok, B. Neyns, G. Linette, S. Négrier, J. Lutzky, L. Thomas, W. Waterfield, D. Schadendorf, M. Smylie, T. Guthrie, J. Grob, J. Chesney, K. Chin, K. Chen, A. Hoos, S. O'Day, C. Lebbé
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma. METHODS We undertook a randomised, double-blind, phase 2 trial in 66 centres from 12 countries. 217 patients with previously treated stage III (unresectable) or stage IV melanoma were randomly assigned a fixed dose of ipilimumab of either 10 mg/kg (n=73), 3 mg/kg (n=72), or 0.3 mg/kg (n=72) every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months. Randomisation was done with a permuted block procedure, stratified on the basis of type of previous treatment. The primary endpoint was best overall response rate (the proportion of patients with a complete or partial response, according to modified WHO criteria). Efficacy analyses were done by intention to treat, whereas safety analyses included patients who received at least one dose of ipilimumab. This study is registered with ClinicalTrials.gov, number NCT00289640. FINDINGS The best overall response rate was 11.1% (95% CI 4.9-20.7) for 10 mg/kg, 4.2% (0.9-11.7) for 3 mg/kg, and 0% (0.0-4.9) for 0.3 mg/kg (p=0.0015; trend test). Immune-related adverse events of any grade arose in 50 of 71, 46 of 71, and 19 of 72 patients at doses of 10 mg/kg, 3 mg/kg, and 0.3 mg/kg, respectively; the most common grade 3-4 adverse events were gastrointestinal immune-related events (11 in the 10 mg/kg group, two in the 3 mg/kg group, none in the 0.3 mg/kg group) and diarrhoea (ten in the 10 mg/kg group, one in the 3 mg/kg group, none in the 0.3 mg/kg group). INTERPRETATION Ipilimumab elicited a dose-dependent effect on efficacy and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg. FUNDING Bristol-Myers Squibb.
This paper references
10.1126/science.271.5256.1734
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
10.1200/JCO.2007.12.7837
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)
10.1093/BIOMET/26.4.404
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
C. J. Clopper (1934)
10.1200/JCO.2008.17.8954
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
L. Fong (2008)
Phase II study to determine predictive markers of response to BMS - 734016 ( MDX - 010 )
A Amin
10.1245/ASO.2005.03.536
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
A. Maker (2005)
10.1200/JCO.2008.26.15_SUPPL.9063
An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy
R. Lin (2008)
10.1073/PNAS.94.15.8099
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.
E. Kwon (1997)
10.1111/j.1529-8019.2005.00052.x
Cutaneous melanoma: available therapy for metastatic disease
A. Tarhini (2006)
10.1073/pnas.1533209100
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
10.1007/s00262-008-0653-8
Ipilimumab: controversies in its development, utility and autoimmune adverse events
J. Weber (2008)
10.1200/JCO.2008.26.15_SUPPL.9021
Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies
S. O’Day (2008)
10.1158/1078-0432.CCR-09-1624
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
10.1200/JCO.2006.06.0483
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
A. Bedikian (2006)
10.1158/1078-0432.CCR-09-1024
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
10.2307/2530286
A Confidence Interval for the Median Survival Time
R. Brookmeyer (1982)
Study of ipilimumab ( MDX - 010 ) monotherapy in patients with previously treated unresectable stage III or IV melanoma A companion study for patients enrolled in prior / parent ipilimumab studies
JD Wolchok
10.1073/pnas.0830997100
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. S. Hodi (2003)
10.1002/14651858.CD005413.PUB2
Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma.
A. Sasse (2007)
10.1200/JCO.1999.17.7.2105
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
M. Atkins (1999)
10.1016/J.COI.2006.01.011
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
K. Peggs (2006)
10.1517/14712598.7.8.1245
Update on anti-CTLA-4 antibodies in clinical trials
Lee Langer (2007)
10.22237/JMASM/1020254880
Exact Level And Power Of Permutation, Bootstrap, And Asymptotic Tests Of Trend
Chris Corcoran (2002)
10.1056/NEJMRA041245
Management of cutaneous melanoma.
H. Tsao (2004)
10.1200/JCO.2008.16.1927
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
10.1158/1078-0432.CCR-07-0187
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
10.1200/JCO.2009.27.15_SUPPL.9037
Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity.
A. Amin (2009)
10.1002/cncr.23086
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
S. O’Day (2007)
10.1200/JCO.2008.26.15_SUPPL.9022
Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine
Evan M. Hersh (2008)
Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
A. Korman (2005)



This paper is referenced by
10.1016/j.semcancer.2017.03.001
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation.
V. Huber (2017)
10.1210/JC.2016-2300
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
Jeroen de Filette (2016)
Bio-conjugate Approaches for Improved Targeted Toll-like receptor based Immune Adjuvant Vaccines
Katrin Kramer (2016)
10.1159/000478081
Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
S. Hwang (2018)
10.1200/JCO.2013.51.1915
Personal history of prostate cancer and increased risk of incident melanoma in the United States.
W. Li (2013)
10.1073/pnas.1611421113
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
S. Subudhi (2016)
Ipilimumab: a promising immunotherapy for melanoma.
J. Thumar (2010)
Transient acantholytic dermatosis in a patient with prostate cancer.
M. Khan (2020)
Kinetics of Appearance of Immune-Related Adverse Events
M. Postow (2015)
10.1016/j.neurol.2011.07.002
Immunotherapy in human glioblastoma.
A. Szabó (2011)
10.2217/imt.11.77
Use of ipilimumab in melanoma.
A. Rivere (2011)
10.1097/PPO.0b013e31823261db
Beyond Cancer Vaccines: A Reason for Future Optimism With Immunomodulatory Therapy
M. Postow (2011)
10.4999/UHOD.13016
Paradigm Shift in Metastatic Malignant Melanoma
A. Sevinç (2013)
10.6004/jnccn.2019.0018
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
D. Coit (2019)
10.1158/1078-0432.CCR-16-2349
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
S. D'Angelo (2016)
10.1016/j.it.2016.04.005
Patient-Physician Communication in the 21st Century.
C. Friedman (2016)
10.2217/imt.15.87
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
O. Abdel-Rahman (2015)
10.1186/1756-8722-5-3
Current management and novel agents for malignant melanoma
Byung Lee (2012)
Novel melanoma therapies and their side effects.
N. Gonzalez (2016)
10.1111/j.1600-065X.2010.00979.x
Therapeutic cancer vaccines: are we there yet?
C. Klebanoff (2011)
10.1310/HPJ4511-828
Cabazitaxel/Ipilimumab
M. Knauth (2010)
10.1634/theoncologist.2012-0483
Ipilimumab and its toxicities: a multidisciplinary approach.
L. Fecher (2013)
10.1158/2326-6066.CIR-17-0057
Masterful Antibodies: Checkpoint Blockade
N. Lonberg (2017)
10.1007/s11523-017-0495-4
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
C. Prieux-Klotz (2017)
10.2217/EBO.12.28
CTLA-4 inhibitor: Ipilimumab for the treatment of NSCLC
J. Brahmer (2012)
Der Einfluss des koinhibitorischen Rezeptors PD-1 (Programmed death-1) auf die Effizienz einer vakzine-induzierten CD8 + T-Zell Antwort
Fachbereichs Biologie (2013)
10.18632/ONCOTARGET.3549
Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort
J. Nsengimana (2015)
10.1517/14712598.2012.675325
Ipilimumab in the treatment of melanoma
V. Trinh (2012)
10.1016/S0001-4079(19)31343-3
[Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
C. Robert (2014)
10.1002/ijc.25681
Synergistic effects of CTLA‐4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
N. Suárez (2011)
10.1155/2016/9757219
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale
Demytra K Mitsis (2016)
10.1016/J.CMONC.2012.05.007
Maintenance therapy in solid tumors
M. A. Smit (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar